Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is a highly lethal bone cancer with limited targeted treatment options.
• The role of ATRX (Alpha Thalassemia intellectual disability syndrome X-linked) in OS pathogenesis remains incompletely understood.

Purpose of the Study:

• To investigate the functional consequences of decreased ATRX expression in osteosarcoma.
• To identify molecular mechanisms linking ATRX loss to tumor aggressiveness and potential therapeutic targets.

Main Methods:

• In vitro and in vivo cell models of ATRX-deficient OS.
• Analysis of human OS patient data.
• Assessment of signaling pathways, extracellular matrix remodeling, and gene transcription.

Main Results:

• Reduced ATRX expression correlates with increased OS cell growth, migration, invasion, and metastasis.
• ATRX deficiency activates NF-κB signaling, promotes extracellular matrix remodeling, and upregulates integrin αvβ3 expression.
• ATRX-deficient OS cells exhibit heightened sensitivity to integrin signaling inhibition.

Conclusions:

• ATRX functions as a tumor suppressor in osteosarcoma.
• Loss of ATRX creates therapeutic vulnerabilities, particularly to integrin signaling inhibitors.
• Novel molecular pathways involving ATRX, integrin binding, NF-κB, and ETS factors are implicated in OS progression.